共 47 条
[1]
Jang S(2020)Correction to: real-world recurrence rates and economic burden in patients with resected early-stage melanoma Dermatol Ther (Heidelb) 10 985-999
[2]
Poretta T(2012)U.S. Food and Drug Administration approval: peginterferon-alfa-2b for the adjuvant treatment of patients with melanoma Oncologist 17 1323-1328
[3]
Bhagnani T(2018)Adjuvant pembrolizumab versus placebo in resected stage III melanoma N Engl J Med 378 1789-1801
[4]
Harshaw Q(2009)Final version of 2009 AJCC melanoma staging and classification J Clin Oncol 27 6199-6206
[5]
Burke M(2017)Estimation of survival probabilities for use in cost-effectiveness analyses: a comparison of a multi-state modeling survival analysis approach with partitioned survival and Markov decision-analytic modeling Med Decis Mak 37 427-439
[6]
Rao S(2017)Cost-effectiveness analysis in R using a multi-state modeling survival analysis framework: a tutorial Med Decis Mak 37 340-352
[7]
Herndon TM(2007)Tutorial in biostatistics: Competing risk and multi-state models Stat Med 26 2389-2430
[8]
Eggermont AMMM(2017)Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) Lancet 390 1853-1862
[9]
Balch CM(2015)Improved overall survival in melanoma with combined dabrafenib and trametinib N Engl J Med 372 30-39
[10]
Williams C(2015)Nivolumab in previously untreated melanoma without BRAF mutation N Engl J Med 372 320-330